Experimental drug plus radiation aims to tackle returning head and neck cancers
NCT ID NCT07156227
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused radiation. The main goals are to find the safest dose and to see if the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camonsertib (a drug that may stop tumor cell growth) combined with stereotactic body radiation therapy (precise radiation to tumors)
What this could lead to
If it works, this could point toward a new treatment option for patients with head and neck cancer that has returned or cannot be surgically removed.
What could go wrong
This is a very early Phase I trial with only 39 participants, so it is primarily testing safety and dosing. The combination may not effectively control the cancer or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center LAO
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact